Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA

Documenti analoghi

• Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
  di: Baselga, José, et al.
  Pubblicazione: (2011)
• Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
  di: Swain, Sandra M., et al.
  Pubblicazione: (2013)
• Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
  di: Miles, David, et al.
  Pubblicazione: (2013)
• Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
  di: Swain, S. M., et al.
  Pubblicazione: (2014)
• Overall survival benefit with pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer in CLEOPATRA, a randomised Phase 3 study
  di: Swain, Sandra M., et al.
  Pubblicazione: (2013)